Clinical Trials Browser

Suspended × OTHER × Sarcoma × Clear all

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Phase 2 Suspended

18 enrolled 16 charts

LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

NCT07301268 2026-02-03

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Phase 2 Suspended

36 enrolled

CNSSarcoma

Astrocytoma, Glioblastoma, Gliosarcoma

NCT06806228 2025-11-19

Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)

Phase 1 Suspended

10 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT02924714 2022-02-18

SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST

Phase NA Suspended

31 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01921998 2015-02-04

BioACT

Suspended

50 enrolled

LymphoidSarcoma

Lymphoma, Sarcoma

Clinical Trials

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Pembrolizumab in Neoplasms or Lymphomas

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)

SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST

BioACT